SAN FRANCISCO--(BUSINESS WIRE)--New data shows that technology developed by HeartFlow, Inc. could lower the cost of evaluating patients with suspected coronary artery disease by as much as 32 percent. The late-breaking data, presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting and simultaneously published in the Journal of the American College of Cardiology, also demonstrates the potential for use of the HeartFlow® FFRCT Analysis to improve patient quality of life.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
